What does APOTHEEK AMERY do?

APOTHEEK AMERY is a pharmacy in Nieuwpoort. Private Limited, started on 29 February 1984, 1 establishment.

What is the address of APOTHEEK AMERY?

The registered office of APOTHEEK AMERY is located at Kerkstraat 5, 8620 Nieuwpoort.

Is APOTHEEK AMERY still active?

Yes. According to the CBE (29 October 2026) APOTHEEK AMERY is active, legal situation “Normale toestand”, started on 29 February 1984.

Is APOTHEEK AMERY registered on Peppol?

Yes, APOTHEEK AMERY is registered on the Peppol network with ID 0208:0425481590.

What is the enterprise number of APOTHEEK AMERY?

The enterprise number of APOTHEEK AMERY is BE0425481590.

When was APOTHEEK AMERY founded?

APOTHEEK AMERY was founded on 29 February 1984.

Who are the directors of APOTHEEK AMERY?

According to the 2025 annual accounts, the directors of APOTHEEK AMERY are: Sodiap BV, Alexo BV.

Is APOTHEEK AMERY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 February 1984; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did APOTHEEK AMERY make in 2025?

APOTHEEK AMERY posted a profit after taxes of € 15,410 in financial year 2025.

What is the revenue of APOTHEEK AMERY?

As a small company, APOTHEEK AMERY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 222,342.

How much does an employee at APOTHEEK AMERY earn?

The average wage cost per full-time employee at APOTHEEK AMERY was € 90,000 in 2025: staff costs of € 161,959 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does APOTHEEK AMERY have?

According to the 2025 annual accounts, APOTHEEK AMERY has 1.8 full-time equivalents (FTE).

Does APOTHEEK AMERY have a website?

Yes, APOTHEEK AMERY has a website at apotheekamery.be.

APOTHEEK AMERY (Private Limited) - Nieuwpoort

Dossier APOTHEEK AMERY, printed on 29 October 2026 from databakkes.be/en/0425481590/apotheek-amery. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 58 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

APOTHEEK AMERY from Nieuwpoort, company number BE0425481590, closed financial year 2025 with a result of € 15,410 after tax. For that financial year APOTHEEK AMERY recorded a gross margin of € 222,342 and equity of € 227,240. Compared with financial year 2024, the result moved from € 60,289 to € 15,410. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Growing

€ 227,240

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 15,410

▼ 74% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 7,760

▼ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 208,640.

People and assets in 2025

Full-time equivalents

1.8

▼ 1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 161,959

▼ 20% vs 2024

€ 90,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,400

▼ 1% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 185,321

▲ 7% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 19,752

▼ 23% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 352,776 Gross margin 2022: € 352,776 First fiscal year in the series	€ 305,387 Gross margin 2023: € 305,387 ▼ 13% vs 2022 (€ 352,776) Unfavourable step	€ 329,543 Gross margin 2024: € 329,543 ▲ 8% vs 2023 (€ 305,387) Favourable step	€ 222,342 Gross margin 2025: € 222,342 ▼ 33% vs 2024 (€ 329,543) Unfavourable step	▼ 33%
Profit after taxes	€ 152,941 Profit after taxes 2022: € 152,941 First fiscal year in the series	€ 62,100 Profit after taxes 2023: € 62,100 ▼ 59% vs 2022 (€ 152,941) Unfavourable step	€ 60,289 Profit after taxes 2024: € 60,289 ▼ 3% vs 2023 (€ 62,100) Unfavourable step	€ 15,410 Profit after taxes 2025: € 15,410 ▼ 74% vs 2024 (€ 60,289) Unfavourable step	▼ 74%
Equity	€ 1,934,442 Equity 2022: € 1,934,442 First fiscal year in the series	€ 151,542 Equity 2023: € 151,542 ▼ 92% vs 2022 (€ 1,934,442) Unfavourable step	€ 211,831 Equity 2024: € 211,831 ▲ 40% vs 2023 (€ 151,542) Favourable step	€ 227,240 Equity 2025: € 227,240 ▲ 7% vs 2024 (€ 211,831) Favourable step	▲ 7%
Total debts	€ 201,214 Total debts 2022: € 201,214 First fiscal year in the series	€ 434,721 Total debts 2023: € 434,721 ▲ 116% vs 2022 (€ 201,214) Unfavourable step	€ 320,490 Total debts 2024: € 320,490 ▼ 26% vs 2023 (€ 434,721) Favourable step	€ 287,245 Total debts 2025: € 287,245 ▼ 10% vs 2024 (€ 320,490) Favourable step	▼ 10%
Cash	€ 9,403 Cash 2022: € 9,403 First fiscal year in the series	€ 10,273 Cash 2023: € 10,273 ▲ 9% vs 2022 (€ 9,403) Favourable step	€ 8,240 Cash 2024: € 8,240 ▼ 20% vs 2023 (€ 10,273) Unfavourable step	€ 7,760 Cash 2025: € 7,760 ▼ 6% vs 2024 (€ 8,240) Unfavourable step	▼ 6%
Retained profit	€ 1,915,842 Retained profit 2022: € 1,915,842 First fiscal year in the series	€ 132,942 Retained profit 2023: € 132,942 ▼ 93% vs 2022 (€ 1,915,842) Unfavourable step	€ 193,231 Retained profit 2024: € 193,231 ▲ 45% vs 2023 (€ 132,942) Favourable step	€ 208,640 Retained profit 2025: € 208,640 ▲ 8% vs 2024 (€ 193,231) Favourable step	▲ 8%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 1,845,000 Dividend 2023: € 1,845,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 1,845,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 2,135,657 Balance sheet total 2022: € 2,135,657 First fiscal year in the series	€ 586,263 Balance sheet total 2023: € 586,263 ▼ 73% vs 2022 (€ 2,135,657) Unchanged	€ 532,321 Balance sheet total 2024: € 532,321 ▼ 9% vs 2023 (€ 586,263) Unchanged	€ 514,486 Balance sheet total 2025: € 514,486 ▼ 3% vs 2024 (€ 532,321) Unchanged	▼ 3%
Employees (FTE)	2.1 Employees (FTE) 2022: 2.1 First fiscal year in the series	2.8 Employees (FTE) 2023: 2.8 ▲ 0.7 vs 2022 (2.1) Unchanged	2.8 Employees (FTE) 2024: 2.8 Unchanged (2.8) Unchanged	1.8 Employees (FTE) 2025: 1.8 ▼ 1 vs 2024 (2.8) Unchanged	▼ 1

Key figures of APOTHEEK AMERY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to APOTHEEK AMERY?

What happened at APOTHEEK AMERY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: profit of € 15,410 (▼ 74% vs 2024). Source: NBB ↗
2022 Alexo BV became a director. NBB
2020 Sodiap BV became a director. NBB
Feb 29, 1984 New establishment in Nieuwpoort. KBO
Feb 29, 1984 Start of the company according to the CBE. KBO

In short

From € 152,941 profit in 2022 to € 15,410 profit in 2025.

Paid € 110,134 in corporate taxes since 2022.

Best year ever: 2022, with € 152,941 profit.

On average € 123,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

APOTHEEK AMERY

Behind APOTHEEK AMERY are Sodiap BV and Alexo BV. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap BV

Managing director · represented by Tom Goderis

Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more

since 2020

Alexo BV

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kerkstraat 5

8620 Nieuwpoort

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheekamery.be

About

Technologies

AMPAlpine.jsCookie ConsentGoogle FontsGoogle TranslateNginxPlausibleVimeoYouTube EmbedreCAPTCHA

Hosting & Email

Email provider

Microsoft 365

Hosting

UPCLOUD, FI

Website info

HTTPS Ja

Indexable pages 109,812

Languages FR, NL

Features

Webshop Newsletter Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number

0425.481.590

VAT number

BE 0425.481.590

Registered office

Kerkstraat 5, 8620 Nieuwpoort

Names & denominations

APOTHEEK AMERY

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

29 February 1984

Peppol

Active · Active since 6 Jun 2025

Contact

apotheekamery.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

APOTHEEK AMERY

Warning lights

Financials

What happened to APOTHEEK AMERY?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions